Global Cancer Immunotherapies Market Growth 2025-2031
The global Cancer Immunotherapies market size is predicted to grow from US$ million in 2025 to US$ million in 2031; it is expected to grow at a CAGR of %from 2025 to 2031.
The impact of the latest U.S. tariff measures and the corresponding policy responses from countries worldwide on market competitiveness, regional economic performance, and supply chain configurations will be comprehensively evaluated in this report.
Cancer immunotherapy, also called biologic therapy, which can predominantly be classed as a form of targeted therapy, It is designed to stimulate the body's immune system to attack tumours.
United States market for Cancer Immunotherapies is estimated to increase from US$ million in 2024 to US$ million by 2031, at a CAGR of % from 2025 through 2031.
China market for Cancer Immunotherapies is estimated to increase from US$ million in 2024 to US$ million by 2031, at a CAGR of % from 2025 through 2031.
Europe market for Cancer Immunotherapies is estimated to increase from US$ million in 2024 to US$ million by 2031, at a CAGR of % from 2025 through 2031.
Global key Cancer Immunotherapies players cover Amgen, AstraZeneca, Roche, Bristol-Myers Squibb, Bayer, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2024.
LP Information, Inc. (LPI) ' newest research report, the “Cancer Immunotherapies Industry Forecast” looks at past sales and reviews total world Cancer Immunotherapies sales in 2024, providing a comprehensive analysis by region and market sector of projected Cancer Immunotherapies sales for 2025 through 2031. With Cancer Immunotherapies sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Cancer Immunotherapies industry.
This Insight Report provides a comprehensive analysis of the global Cancer Immunotherapies landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Cancer Immunotherapies portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Cancer Immunotherapies market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Cancer Immunotherapies and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Cancer Immunotherapies.
This report presents a comprehensive overview, market shares, and growth opportunities of Cancer Immunotherapies market by product type, application, key manufacturers and key regions and countries.
Segmentation by Type:
What is the 10-year outlook for the global Cancer Immunotherapies market?
What factors are driving Cancer Immunotherapies market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do Cancer Immunotherapies market opportunities vary by end market size?
How does Cancer Immunotherapies break out by Type, by Application?
The impact of the latest U.S. tariff measures and the corresponding policy responses from countries worldwide on market competitiveness, regional economic performance, and supply chain configurations will be comprehensively evaluated in this report.
Cancer immunotherapy, also called biologic therapy, which can predominantly be classed as a form of targeted therapy, It is designed to stimulate the body's immune system to attack tumours.
United States market for Cancer Immunotherapies is estimated to increase from US$ million in 2024 to US$ million by 2031, at a CAGR of % from 2025 through 2031.
China market for Cancer Immunotherapies is estimated to increase from US$ million in 2024 to US$ million by 2031, at a CAGR of % from 2025 through 2031.
Europe market for Cancer Immunotherapies is estimated to increase from US$ million in 2024 to US$ million by 2031, at a CAGR of % from 2025 through 2031.
Global key Cancer Immunotherapies players cover Amgen, AstraZeneca, Roche, Bristol-Myers Squibb, Bayer, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2024.
LP Information, Inc. (LPI) ' newest research report, the “Cancer Immunotherapies Industry Forecast” looks at past sales and reviews total world Cancer Immunotherapies sales in 2024, providing a comprehensive analysis by region and market sector of projected Cancer Immunotherapies sales for 2025 through 2031. With Cancer Immunotherapies sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Cancer Immunotherapies industry.
This Insight Report provides a comprehensive analysis of the global Cancer Immunotherapies landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Cancer Immunotherapies portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Cancer Immunotherapies market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Cancer Immunotherapies and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Cancer Immunotherapies.
This report presents a comprehensive overview, market shares, and growth opportunities of Cancer Immunotherapies market by product type, application, key manufacturers and key regions and countries.
Segmentation by Type:
- Monoclonal Antibodies (MABs)
- Cancer Vaccines
- Immunomodulators
- Adoptive Cell transfer
- Checkpoint Inhibitors
- Breast Cancer
- Leukemia
- Lymphoma
- Melanoma
- Colorectal Cancer
- Non-Small Cell Lung Cancer
- Americas
- United States
- Canada
- Mexico
- Brazil
- APAC
- China
- Japan
- Korea
- Southeast Asia
- India
- Australia
- Europe
- Germany
- France
- UK
- Italy
- Russia
- Middle East & Africa
- Egypt
- South Africa
- Israel
- Turkey
- GCC Countries
- Amgen
- AstraZeneca
- Roche
- Bristol-Myers Squibb
- Bayer
- Merck
- ARMO BioSciences (Eli Lilly)
- Novartis
- Pfizer
- Johnson & Johnson
- AbbVie
- Gilead Sciences
What is the 10-year outlook for the global Cancer Immunotherapies market?
What factors are driving Cancer Immunotherapies market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do Cancer Immunotherapies market opportunities vary by end market size?
How does Cancer Immunotherapies break out by Type, by Application?
1 SCOPE OF THE REPORT
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 EXECUTIVE SUMMARY
2.1 World Market Overview
2.1.1 Global Cancer Immunotherapies Annual Sales 2020-2031
2.1.2 World Current & Future Analysis for Cancer Immunotherapies by Geographic Region, 2020, 2024 & 2031
2.1.3 World Current & Future Analysis for Cancer Immunotherapies by Country/Region, 2020, 2024 & 2031
2.2 Cancer Immunotherapies Segment by Type
2.2.1 Monoclonal Antibodies (MABs)
2.2.2 Cancer Vaccines
2.2.3 Immunomodulators
2.2.4 Adoptive Cell transfer
2.2.5 Checkpoint Inhibitors
2.3 Cancer Immunotherapies Sales by Type
2.3.1 Global Cancer Immunotherapies Sales Market Share by Type (2020-2025)
2.3.2 Global Cancer Immunotherapies Revenue and Market Share by Type (2020-2025)
2.3.3 Global Cancer Immunotherapies Sale Price by Type (2020-2025)
2.4 Cancer Immunotherapies Segment by Application
2.4.1 Breast Cancer
2.4.2 Leukemia
2.4.3 Lymphoma
2.4.4 Melanoma
2.4.5 Colorectal Cancer
2.4.6 Non-Small Cell Lung Cancer
2.5 Cancer Immunotherapies Sales by Application
2.5.1 Global Cancer Immunotherapies Sale Market Share by Application (2020-2025)
2.5.2 Global Cancer Immunotherapies Revenue and Market Share by Application (2020-2025)
2.5.3 Global Cancer Immunotherapies Sale Price by Application (2020-2025)
3 GLOBAL BY COMPANY
3.1 Global Cancer Immunotherapies Breakdown Data by Company
3.1.1 Global Cancer Immunotherapies Annual Sales by Company (2020-2025)
3.1.2 Global Cancer Immunotherapies Sales Market Share by Company (2020-2025)
3.2 Global Cancer Immunotherapies Annual Revenue by Company (2020-2025)
3.2.1 Global Cancer Immunotherapies Revenue by Company (2020-2025)
3.2.2 Global Cancer Immunotherapies Revenue Market Share by Company (2020-2025)
3.3 Global Cancer Immunotherapies Sale Price by Company
3.4 Key Manufacturers Cancer Immunotherapies Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers Cancer Immunotherapies Product Location Distribution
3.4.2 Players Cancer Immunotherapies Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2023-2025)
3.6 New Products and Potential Entrants
3.7 Market M&A Activity & Strategy
4 WORLD HISTORIC REVIEW FOR CANCER IMMUNOTHERAPIES BY GEOGRAPHIC REGION
4.1 World Historic Cancer Immunotherapies Market Size by Geographic Region (2020-2025)
4.1.1 Global Cancer Immunotherapies Annual Sales by Geographic Region (2020-2025)
4.1.2 Global Cancer Immunotherapies Annual Revenue by Geographic Region (2020-2025)
4.2 World Historic Cancer Immunotherapies Market Size by Country/Region (2020-2025)
4.2.1 Global Cancer Immunotherapies Annual Sales by Country/Region (2020-2025)
4.2.2 Global Cancer Immunotherapies Annual Revenue by Country/Region (2020-2025)
4.3 Americas Cancer Immunotherapies Sales Growth
4.4 APAC Cancer Immunotherapies Sales Growth
4.5 Europe Cancer Immunotherapies Sales Growth
4.6 Middle East & Africa Cancer Immunotherapies Sales Growth
5 AMERICAS
5.1 Americas Cancer Immunotherapies Sales by Country
5.1.1 Americas Cancer Immunotherapies Sales by Country (2020-2025)
5.1.2 Americas Cancer Immunotherapies Revenue by Country (2020-2025)
5.2 Americas Cancer Immunotherapies Sales by Type (2020-2025)
5.3 Americas Cancer Immunotherapies Sales by Application (2020-2025)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Cancer Immunotherapies Sales by Region
6.1.1 APAC Cancer Immunotherapies Sales by Region (2020-2025)
6.1.2 APAC Cancer Immunotherapies Revenue by Region (2020-2025)
6.2 APAC Cancer Immunotherapies Sales by Type (2020-2025)
6.3 APAC Cancer Immunotherapies Sales by Application (2020-2025)
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan
7 EUROPE
7.1 Europe Cancer Immunotherapies by Country
7.1.1 Europe Cancer Immunotherapies Sales by Country (2020-2025)
7.1.2 Europe Cancer Immunotherapies Revenue by Country (2020-2025)
7.2 Europe Cancer Immunotherapies Sales by Type (2020-2025)
7.3 Europe Cancer Immunotherapies Sales by Application (2020-2025)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 MIDDLE EAST & AFRICA
8.1 Middle East & Africa Cancer Immunotherapies by Country
8.1.1 Middle East & Africa Cancer Immunotherapies Sales by Country (2020-2025)
8.1.2 Middle East & Africa Cancer Immunotherapies Revenue by Country (2020-2025)
8.2 Middle East & Africa Cancer Immunotherapies Sales by Type (2020-2025)
8.3 Middle East & Africa Cancer Immunotherapies Sales by Application (2020-2025)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 MARKET DRIVERS, CHALLENGES AND TRENDS
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 MANUFACTURING COST STRUCTURE ANALYSIS
10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of Cancer Immunotherapies
10.3 Manufacturing Process Analysis of Cancer Immunotherapies
10.4 Industry Chain Structure of Cancer Immunotherapies
11 MARKETING, DISTRIBUTORS AND CUSTOMER
11.1 Sales Channel
11.1.1 Direct Channels
11.1.2 Indirect Channels
11.2 Cancer Immunotherapies Distributors
11.3 Cancer Immunotherapies Customer
12 WORLD FORECAST REVIEW FOR CANCER IMMUNOTHERAPIES BY GEOGRAPHIC REGION
12.1 Global Cancer Immunotherapies Market Size Forecast by Region
12.1.1 Global Cancer Immunotherapies Forecast by Region (2026-2031)
12.1.2 Global Cancer Immunotherapies Annual Revenue Forecast by Region (2026-2031)
12.2 Americas Forecast by Country (2026-2031)
12.3 APAC Forecast by Region (2026-2031)
12.4 Europe Forecast by Country (2026-2031)
12.5 Middle East & Africa Forecast by Country (2026-2031)
12.6 Global Cancer Immunotherapies Forecast by Type (2026-2031)
12.7 Global Cancer Immunotherapies Forecast by Application (2026-2031)
13 KEY PLAYERS ANALYSIS
13.1 Amgen
13.1.1 Amgen Company Information
13.1.2 Amgen Cancer Immunotherapies Product Portfolios and Specifications
13.1.3 Amgen Cancer Immunotherapies Sales, Revenue, Price and Gross Margin (2020-2025)
13.1.4 Amgen Main Business Overview
13.1.5 Amgen Latest Developments
13.2 AstraZeneca
13.2.1 AstraZeneca Company Information
13.2.2 AstraZeneca Cancer Immunotherapies Product Portfolios and Specifications
13.2.3 AstraZeneca Cancer Immunotherapies Sales, Revenue, Price and Gross Margin (2020-2025)
13.2.4 AstraZeneca Main Business Overview
13.2.5 AstraZeneca Latest Developments
13.3 Roche
13.3.1 Roche Company Information
13.3.2 Roche Cancer Immunotherapies Product Portfolios and Specifications
13.3.3 Roche Cancer Immunotherapies Sales, Revenue, Price and Gross Margin (2020-2025)
13.3.4 Roche Main Business Overview
13.3.5 Roche Latest Developments
13.4 Bristol-Myers Squibb
13.4.1 Bristol-Myers Squibb Company Information
13.4.2 Bristol-Myers Squibb Cancer Immunotherapies Product Portfolios and Specifications
13.4.3 Bristol-Myers Squibb Cancer Immunotherapies Sales, Revenue, Price and Gross Margin (2020-2025)
13.4.4 Bristol-Myers Squibb Main Business Overview
13.4.5 Bristol-Myers Squibb Latest Developments
13.5 Bayer
13.5.1 Bayer Company Information
13.5.2 Bayer Cancer Immunotherapies Product Portfolios and Specifications
13.5.3 Bayer Cancer Immunotherapies Sales, Revenue, Price and Gross Margin (2020-2025)
13.5.4 Bayer Main Business Overview
13.5.5 Bayer Latest Developments
13.6 Merck
13.6.1 Merck Company Information
13.6.2 Merck Cancer Immunotherapies Product Portfolios and Specifications
13.6.3 Merck Cancer Immunotherapies Sales, Revenue, Price and Gross Margin (2020-2025)
13.6.4 Merck Main Business Overview
13.6.5 Merck Latest Developments
13.7 ARMO BioSciences (Eli Lilly)
13.7.1 ARMO BioSciences (Eli Lilly) Company Information
13.7.2 ARMO BioSciences (Eli Lilly) Cancer Immunotherapies Product Portfolios and Specifications
13.7.3 ARMO BioSciences (Eli Lilly) Cancer Immunotherapies Sales, Revenue, Price and Gross Margin (2020-2025)
13.7.4 ARMO BioSciences (Eli Lilly) Main Business Overview
13.7.5 ARMO BioSciences (Eli Lilly) Latest Developments
13.8 Novartis
13.8.1 Novartis Company Information
13.8.2 Novartis Cancer Immunotherapies Product Portfolios and Specifications
13.8.3 Novartis Cancer Immunotherapies Sales, Revenue, Price and Gross Margin (2020-2025)
13.8.4 Novartis Main Business Overview
13.8.5 Novartis Latest Developments
13.9 Pfizer
13.9.1 Pfizer Company Information
13.9.2 Pfizer Cancer Immunotherapies Product Portfolios and Specifications
13.9.3 Pfizer Cancer Immunotherapies Sales, Revenue, Price and Gross Margin (2020-2025)
13.9.4 Pfizer Main Business Overview
13.9.5 Pfizer Latest Developments
13.10 Johnson & Johnson
13.10.1 Johnson & Johnson Company Information
13.10.2 Johnson & Johnson Cancer Immunotherapies Product Portfolios and Specifications
13.10.3 Johnson & Johnson Cancer Immunotherapies Sales, Revenue, Price and Gross Margin (2020-2025)
13.10.4 Johnson & Johnson Main Business Overview
13.10.5 Johnson & Johnson Latest Developments
13.11 AbbVie
13.11.1 AbbVie Company Information
13.11.2 AbbVie Cancer Immunotherapies Product Portfolios and Specifications
13.11.3 AbbVie Cancer Immunotherapies Sales, Revenue, Price and Gross Margin (2020-2025)
13.11.4 AbbVie Main Business Overview
13.11.5 AbbVie Latest Developments
13.12 Gilead Sciences
13.12.1 Gilead Sciences Company Information
13.12.2 Gilead Sciences Cancer Immunotherapies Product Portfolios and Specifications
13.12.3 Gilead Sciences Cancer Immunotherapies Sales, Revenue, Price and Gross Margin (2020-2025)
13.12.4 Gilead Sciences Main Business Overview
13.12.5 Gilead Sciences Latest Developments
14 RESEARCH FINDINGS AND CONCLUSION
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 EXECUTIVE SUMMARY
2.1 World Market Overview
2.1.1 Global Cancer Immunotherapies Annual Sales 2020-2031
2.1.2 World Current & Future Analysis for Cancer Immunotherapies by Geographic Region, 2020, 2024 & 2031
2.1.3 World Current & Future Analysis for Cancer Immunotherapies by Country/Region, 2020, 2024 & 2031
2.2 Cancer Immunotherapies Segment by Type
2.2.1 Monoclonal Antibodies (MABs)
2.2.2 Cancer Vaccines
2.2.3 Immunomodulators
2.2.4 Adoptive Cell transfer
2.2.5 Checkpoint Inhibitors
2.3 Cancer Immunotherapies Sales by Type
2.3.1 Global Cancer Immunotherapies Sales Market Share by Type (2020-2025)
2.3.2 Global Cancer Immunotherapies Revenue and Market Share by Type (2020-2025)
2.3.3 Global Cancer Immunotherapies Sale Price by Type (2020-2025)
2.4 Cancer Immunotherapies Segment by Application
2.4.1 Breast Cancer
2.4.2 Leukemia
2.4.3 Lymphoma
2.4.4 Melanoma
2.4.5 Colorectal Cancer
2.4.6 Non-Small Cell Lung Cancer
2.5 Cancer Immunotherapies Sales by Application
2.5.1 Global Cancer Immunotherapies Sale Market Share by Application (2020-2025)
2.5.2 Global Cancer Immunotherapies Revenue and Market Share by Application (2020-2025)
2.5.3 Global Cancer Immunotherapies Sale Price by Application (2020-2025)
3 GLOBAL BY COMPANY
3.1 Global Cancer Immunotherapies Breakdown Data by Company
3.1.1 Global Cancer Immunotherapies Annual Sales by Company (2020-2025)
3.1.2 Global Cancer Immunotherapies Sales Market Share by Company (2020-2025)
3.2 Global Cancer Immunotherapies Annual Revenue by Company (2020-2025)
3.2.1 Global Cancer Immunotherapies Revenue by Company (2020-2025)
3.2.2 Global Cancer Immunotherapies Revenue Market Share by Company (2020-2025)
3.3 Global Cancer Immunotherapies Sale Price by Company
3.4 Key Manufacturers Cancer Immunotherapies Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers Cancer Immunotherapies Product Location Distribution
3.4.2 Players Cancer Immunotherapies Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2023-2025)
3.6 New Products and Potential Entrants
3.7 Market M&A Activity & Strategy
4 WORLD HISTORIC REVIEW FOR CANCER IMMUNOTHERAPIES BY GEOGRAPHIC REGION
4.1 World Historic Cancer Immunotherapies Market Size by Geographic Region (2020-2025)
4.1.1 Global Cancer Immunotherapies Annual Sales by Geographic Region (2020-2025)
4.1.2 Global Cancer Immunotherapies Annual Revenue by Geographic Region (2020-2025)
4.2 World Historic Cancer Immunotherapies Market Size by Country/Region (2020-2025)
4.2.1 Global Cancer Immunotherapies Annual Sales by Country/Region (2020-2025)
4.2.2 Global Cancer Immunotherapies Annual Revenue by Country/Region (2020-2025)
4.3 Americas Cancer Immunotherapies Sales Growth
4.4 APAC Cancer Immunotherapies Sales Growth
4.5 Europe Cancer Immunotherapies Sales Growth
4.6 Middle East & Africa Cancer Immunotherapies Sales Growth
5 AMERICAS
5.1 Americas Cancer Immunotherapies Sales by Country
5.1.1 Americas Cancer Immunotherapies Sales by Country (2020-2025)
5.1.2 Americas Cancer Immunotherapies Revenue by Country (2020-2025)
5.2 Americas Cancer Immunotherapies Sales by Type (2020-2025)
5.3 Americas Cancer Immunotherapies Sales by Application (2020-2025)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Cancer Immunotherapies Sales by Region
6.1.1 APAC Cancer Immunotherapies Sales by Region (2020-2025)
6.1.2 APAC Cancer Immunotherapies Revenue by Region (2020-2025)
6.2 APAC Cancer Immunotherapies Sales by Type (2020-2025)
6.3 APAC Cancer Immunotherapies Sales by Application (2020-2025)
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan
7 EUROPE
7.1 Europe Cancer Immunotherapies by Country
7.1.1 Europe Cancer Immunotherapies Sales by Country (2020-2025)
7.1.2 Europe Cancer Immunotherapies Revenue by Country (2020-2025)
7.2 Europe Cancer Immunotherapies Sales by Type (2020-2025)
7.3 Europe Cancer Immunotherapies Sales by Application (2020-2025)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 MIDDLE EAST & AFRICA
8.1 Middle East & Africa Cancer Immunotherapies by Country
8.1.1 Middle East & Africa Cancer Immunotherapies Sales by Country (2020-2025)
8.1.2 Middle East & Africa Cancer Immunotherapies Revenue by Country (2020-2025)
8.2 Middle East & Africa Cancer Immunotherapies Sales by Type (2020-2025)
8.3 Middle East & Africa Cancer Immunotherapies Sales by Application (2020-2025)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 MARKET DRIVERS, CHALLENGES AND TRENDS
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 MANUFACTURING COST STRUCTURE ANALYSIS
10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of Cancer Immunotherapies
10.3 Manufacturing Process Analysis of Cancer Immunotherapies
10.4 Industry Chain Structure of Cancer Immunotherapies
11 MARKETING, DISTRIBUTORS AND CUSTOMER
11.1 Sales Channel
11.1.1 Direct Channels
11.1.2 Indirect Channels
11.2 Cancer Immunotherapies Distributors
11.3 Cancer Immunotherapies Customer
12 WORLD FORECAST REVIEW FOR CANCER IMMUNOTHERAPIES BY GEOGRAPHIC REGION
12.1 Global Cancer Immunotherapies Market Size Forecast by Region
12.1.1 Global Cancer Immunotherapies Forecast by Region (2026-2031)
12.1.2 Global Cancer Immunotherapies Annual Revenue Forecast by Region (2026-2031)
12.2 Americas Forecast by Country (2026-2031)
12.3 APAC Forecast by Region (2026-2031)
12.4 Europe Forecast by Country (2026-2031)
12.5 Middle East & Africa Forecast by Country (2026-2031)
12.6 Global Cancer Immunotherapies Forecast by Type (2026-2031)
12.7 Global Cancer Immunotherapies Forecast by Application (2026-2031)
13 KEY PLAYERS ANALYSIS
13.1 Amgen
13.1.1 Amgen Company Information
13.1.2 Amgen Cancer Immunotherapies Product Portfolios and Specifications
13.1.3 Amgen Cancer Immunotherapies Sales, Revenue, Price and Gross Margin (2020-2025)
13.1.4 Amgen Main Business Overview
13.1.5 Amgen Latest Developments
13.2 AstraZeneca
13.2.1 AstraZeneca Company Information
13.2.2 AstraZeneca Cancer Immunotherapies Product Portfolios and Specifications
13.2.3 AstraZeneca Cancer Immunotherapies Sales, Revenue, Price and Gross Margin (2020-2025)
13.2.4 AstraZeneca Main Business Overview
13.2.5 AstraZeneca Latest Developments
13.3 Roche
13.3.1 Roche Company Information
13.3.2 Roche Cancer Immunotherapies Product Portfolios and Specifications
13.3.3 Roche Cancer Immunotherapies Sales, Revenue, Price and Gross Margin (2020-2025)
13.3.4 Roche Main Business Overview
13.3.5 Roche Latest Developments
13.4 Bristol-Myers Squibb
13.4.1 Bristol-Myers Squibb Company Information
13.4.2 Bristol-Myers Squibb Cancer Immunotherapies Product Portfolios and Specifications
13.4.3 Bristol-Myers Squibb Cancer Immunotherapies Sales, Revenue, Price and Gross Margin (2020-2025)
13.4.4 Bristol-Myers Squibb Main Business Overview
13.4.5 Bristol-Myers Squibb Latest Developments
13.5 Bayer
13.5.1 Bayer Company Information
13.5.2 Bayer Cancer Immunotherapies Product Portfolios and Specifications
13.5.3 Bayer Cancer Immunotherapies Sales, Revenue, Price and Gross Margin (2020-2025)
13.5.4 Bayer Main Business Overview
13.5.5 Bayer Latest Developments
13.6 Merck
13.6.1 Merck Company Information
13.6.2 Merck Cancer Immunotherapies Product Portfolios and Specifications
13.6.3 Merck Cancer Immunotherapies Sales, Revenue, Price and Gross Margin (2020-2025)
13.6.4 Merck Main Business Overview
13.6.5 Merck Latest Developments
13.7 ARMO BioSciences (Eli Lilly)
13.7.1 ARMO BioSciences (Eli Lilly) Company Information
13.7.2 ARMO BioSciences (Eli Lilly) Cancer Immunotherapies Product Portfolios and Specifications
13.7.3 ARMO BioSciences (Eli Lilly) Cancer Immunotherapies Sales, Revenue, Price and Gross Margin (2020-2025)
13.7.4 ARMO BioSciences (Eli Lilly) Main Business Overview
13.7.5 ARMO BioSciences (Eli Lilly) Latest Developments
13.8 Novartis
13.8.1 Novartis Company Information
13.8.2 Novartis Cancer Immunotherapies Product Portfolios and Specifications
13.8.3 Novartis Cancer Immunotherapies Sales, Revenue, Price and Gross Margin (2020-2025)
13.8.4 Novartis Main Business Overview
13.8.5 Novartis Latest Developments
13.9 Pfizer
13.9.1 Pfizer Company Information
13.9.2 Pfizer Cancer Immunotherapies Product Portfolios and Specifications
13.9.3 Pfizer Cancer Immunotherapies Sales, Revenue, Price and Gross Margin (2020-2025)
13.9.4 Pfizer Main Business Overview
13.9.5 Pfizer Latest Developments
13.10 Johnson & Johnson
13.10.1 Johnson & Johnson Company Information
13.10.2 Johnson & Johnson Cancer Immunotherapies Product Portfolios and Specifications
13.10.3 Johnson & Johnson Cancer Immunotherapies Sales, Revenue, Price and Gross Margin (2020-2025)
13.10.4 Johnson & Johnson Main Business Overview
13.10.5 Johnson & Johnson Latest Developments
13.11 AbbVie
13.11.1 AbbVie Company Information
13.11.2 AbbVie Cancer Immunotherapies Product Portfolios and Specifications
13.11.3 AbbVie Cancer Immunotherapies Sales, Revenue, Price and Gross Margin (2020-2025)
13.11.4 AbbVie Main Business Overview
13.11.5 AbbVie Latest Developments
13.12 Gilead Sciences
13.12.1 Gilead Sciences Company Information
13.12.2 Gilead Sciences Cancer Immunotherapies Product Portfolios and Specifications
13.12.3 Gilead Sciences Cancer Immunotherapies Sales, Revenue, Price and Gross Margin (2020-2025)
13.12.4 Gilead Sciences Main Business Overview
13.12.5 Gilead Sciences Latest Developments
14 RESEARCH FINDINGS AND CONCLUSION
LIST OF TABLES
Table 1. Cancer Immunotherapies Annual Sales CAGR by Geographic Region (2020, 2024 & 2031) & ($ millions)
Table 2. Cancer Immunotherapies Annual Sales CAGR by Country/Region (2020, 2024 & 2031) & ($ millions)
Table 3. Major Players of Monoclonal Antibodies (MABs)
Table 4. Major Players of Cancer Vaccines
Table 5. Major Players of Immunomodulators
Table 6. Major Players of Adoptive Cell transfer
Table 7. Major Players of Checkpoint Inhibitors
Table 8. Global Cancer Immunotherapies Sales by Type (2020-2025) & (K Units)
Table 9. Global Cancer Immunotherapies Sales Market Share by Type (2020-2025)
Table 10. Global Cancer Immunotherapies Revenue by Type (2020-2025) & ($ million)
Table 11. Global Cancer Immunotherapies Revenue Market Share by Type (2020-2025)
Table 12. Global Cancer Immunotherapies Sale Price by Type (2020-2025) & (USD/Unit)
Table 13. Global Cancer Immunotherapies Sale by Application (2020-2025) & (K Units)
Table 14. Global Cancer Immunotherapies Sale Market Share by Application (2020-2025)
Table 15. Global Cancer Immunotherapies Revenue by Application (2020-2025) & ($ million)
Table 16. Global Cancer Immunotherapies Revenue Market Share by Application (2020-2025)
Table 17. Global Cancer Immunotherapies Sale Price by Application (2020-2025) & (USD/Unit)
Table 18. Global Cancer Immunotherapies Sales by Company (2020-2025) & (K Units)
Table 19. Global Cancer Immunotherapies Sales Market Share by Company (2020-2025)
Table 20. Global Cancer Immunotherapies Revenue by Company (2020-2025) & ($ millions)
Table 21. Global Cancer Immunotherapies Revenue Market Share by Company (2020-2025)
Table 22. Global Cancer Immunotherapies Sale Price by Company (2020-2025) & (USD/Unit)
Table 23. Key Manufacturers Cancer Immunotherapies Producing Area Distribution and Sales Area
Table 24. Players Cancer Immunotherapies Products Offered
Table 25. Cancer Immunotherapies Concentration Ratio (CR3, CR5 and CR10) & (2023-2025)
Table 26. New Products and Potential Entrants
Table 27. Market M&A Activity & Strategy
Table 28. Global Cancer Immunotherapies Sales by Geographic Region (2020-2025) & (K Units)
Table 29. Global Cancer Immunotherapies Sales Market Share Geographic Region (2020-2025)
Table 30. Global Cancer Immunotherapies Revenue by Geographic Region (2020-2025) & ($ millions)
Table 31. Global Cancer Immunotherapies Revenue Market Share by Geographic Region (2020-2025)
Table 32. Global Cancer Immunotherapies Sales by Country/Region (2020-2025) & (K Units)
Table 33. Global Cancer Immunotherapies Sales Market Share by Country/Region (2020-2025)
Table 34. Global Cancer Immunotherapies Revenue by Country/Region (2020-2025) & ($ millions)
Table 35. Global Cancer Immunotherapies Revenue Market Share by Country/Region (2020-2025)
Table 36. Americas Cancer Immunotherapies Sales by Country (2020-2025) & (K Units)
Table 37. Americas Cancer Immunotherapies Sales Market Share by Country (2020-2025)
Table 38. Americas Cancer Immunotherapies Revenue by Country (2020-2025) & ($ millions)
Table 39. Americas Cancer Immunotherapies Sales by Type (2020-2025) & (K Units)
Table 40. Americas Cancer Immunotherapies Sales by Application (2020-2025) & (K Units)
Table 41. APAC Cancer Immunotherapies Sales by Region (2020-2025) & (K Units)
Table 42. APAC Cancer Immunotherapies Sales Market Share by Region (2020-2025)
Table 43. APAC Cancer Immunotherapies Revenue by Region (2020-2025) & ($ millions)
Table 44. APAC Cancer Immunotherapies Sales by Type (2020-2025) & (K Units)
Table 45. APAC Cancer Immunotherapies Sales by Application (2020-2025) & (K Units)
Table 46. Europe Cancer Immunotherapies Sales by Country (2020-2025) & (K Units)
Table 47. Europe Cancer Immunotherapies Revenue by Country (2020-2025) & ($ millions)
Table 48. Europe Cancer Immunotherapies Sales by Type (2020-2025) & (K Units)
Table 49. Europe Cancer Immunotherapies Sales by Application (2020-2025) & (K Units)
Table 50. Middle East & Africa Cancer Immunotherapies Sales by Country (2020-2025) & (K Units)
Table 51. Middle East & Africa Cancer Immunotherapies Revenue Market Share by Country (2020-2025)
Table 52. Middle East & Africa Cancer Immunotherapies Sales by Type (2020-2025) & (K Units)
Table 53. Middle East & Africa Cancer Immunotherapies Sales by Application (2020-2025) & (K Units)
Table 54. Key Market Drivers & Growth Opportunities of Cancer Immunotherapies
Table 55. Key Market Challenges & Risks of Cancer Immunotherapies
Table 56. Key Industry Trends of Cancer Immunotherapies
Table 57. Cancer Immunotherapies Raw Material
Table 58. Key Suppliers of Raw Materials
Table 59. Cancer Immunotherapies Distributors List
Table 60. Cancer Immunotherapies Customer List
Table 61. Global Cancer Immunotherapies Sales Forecast by Region (2026-2031) & (K Units)
Table 62. Global Cancer Immunotherapies Revenue Forecast by Region (2026-2031) & ($ millions)
Table 63. Americas Cancer Immunotherapies Sales Forecast by Country (2026-2031) & (K Units)
Table 64. Americas Cancer Immunotherapies Annual Revenue Forecast by Country (2026-2031) & ($ millions)
Table 65. APAC Cancer Immunotherapies Sales Forecast by Region (2026-2031) & (K Units)
Table 66. APAC Cancer Immunotherapies Annual Revenue Forecast by Region (2026-2031) & ($ millions)
Table 67. Europe Cancer Immunotherapies Sales Forecast by Country (2026-2031) & (K Units)
Table 68. Europe Cancer Immunotherapies Revenue Forecast by Country (2026-2031) & ($ millions)
Table 69. Middle East & Africa Cancer Immunotherapies Sales Forecast by Country (2026-2031) & (K Units)
Table 70. Middle East & Africa Cancer Immunotherapies Revenue Forecast by Country (2026-2031) & ($ millions)
Table 71. Global Cancer Immunotherapies Sales Forecast by Type (2026-2031) & (K Units)
Table 72. Global Cancer Immunotherapies Revenue Forecast by Type (2026-2031) & ($ millions)
Table 73. Global Cancer Immunotherapies Sales Forecast by Application (2026-2031) & (K Units)
Table 74. Global Cancer Immunotherapies Revenue Forecast by Application (2026-2031) & ($ millions)
Table 75. Amgen Basic Information, Cancer Immunotherapies Manufacturing Base, Sales Area and Its Competitors
Table 76. Amgen Cancer Immunotherapies Product Portfolios and Specifications
Table 77. Amgen Cancer Immunotherapies Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2020-2025)
Table 78. Amgen Main Business
Table 79. Amgen Latest Developments
Table 80. AstraZeneca Basic Information, Cancer Immunotherapies Manufacturing Base, Sales Area and Its Competitors
Table 81. AstraZeneca Cancer Immunotherapies Product Portfolios and Specifications
Table 82. AstraZeneca Cancer Immunotherapies Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2020-2025)
Table 83. AstraZeneca Main Business
Table 84. AstraZeneca Latest Developments
Table 85. Roche Basic Information, Cancer Immunotherapies Manufacturing Base, Sales Area and Its Competitors
Table 86. Roche Cancer Immunotherapies Product Portfolios and Specifications
Table 87. Roche Cancer Immunotherapies Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2020-2025)
Table 88. Roche Main Business
Table 89. Roche Latest Developments
Table 90. Bristol-Myers Squibb Basic Information, Cancer Immunotherapies Manufacturing Base, Sales Area and Its Competitors
Table 91. Bristol-Myers Squibb Cancer Immunotherapies Product Portfolios and Specifications
Table 92. Bristol-Myers Squibb Cancer Immunotherapies Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2020-2025)
Table 93. Bristol-Myers Squibb Main Business
Table 94. Bristol-Myers Squibb Latest Developments
Table 95. Bayer Basic Information, Cancer Immunotherapies Manufacturing Base, Sales Area and Its Competitors
Table 96. Bayer Cancer Immunotherapies Product Portfolios and Specifications
Table 97. Bayer Cancer Immunotherapies Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2020-2025)
Table 98. Bayer Main Business
Table 99. Bayer Latest Developments
Table 100. Merck Basic Information, Cancer Immunotherapies Manufacturing Base, Sales Area and Its Competitors
Table 101. Merck Cancer Immunotherapies Product Portfolios and Specifications
Table 102. Merck Cancer Immunotherapies Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2020-2025)
Table 103. Merck Main Business
Table 104. Merck Latest Developments
Table 105. ARMO BioSciences (Eli Lilly) Basic Information, Cancer Immunotherapies Manufacturing Base, Sales Area and Its Competitors
Table 106. ARMO BioSciences (Eli Lilly) Cancer Immunotherapies Product Portfolios and Specifications
Table 107. ARMO BioSciences (Eli Lilly) Cancer Immunotherapies Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2020-2025)
Table 108. ARMO BioSciences (Eli Lilly) Main Business
Table 109. ARMO BioSciences (Eli Lilly) Latest Developments
Table 110. Novartis Basic Information, Cancer Immunotherapies Manufacturing Base, Sales Area and Its Competitors
Table 111. Novartis Cancer Immunotherapies Product Portfolios and Specifications
Table 112. Novartis Cancer Immunotherapies Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2020-2025)
Table 113. Novartis Main Business
Table 114. Novartis Latest Developments
Table 115. Pfizer Basic Information, Cancer Immunotherapies Manufacturing Base, Sales Area and Its Competitors
Table 116. Pfizer Cancer Immunotherapies Product Portfolios and Specifications
Table 117. Pfizer Cancer Immunotherapies Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2020-2025)
Table 118. Pfizer Main Business
Table 119. Pfizer Latest Developments
Table 120. Johnson & Johnson Basic Information, Cancer Immunotherapies Manufacturing Base, Sales Area and Its Competitors
Table 121. Johnson & Johnson Cancer Immunotherapies Product Portfolios and Specifications
Table 122. Johnson & Johnson Cancer Immunotherapies Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2020-2025)
Table 123. Johnson & Johnson Main Business
Table 124. Johnson & Johnson Latest Developments
Table 125. AbbVie Basic Information, Cancer Immunotherapies Manufacturing Base, Sales Area and Its Competitors
Table 126. AbbVie Cancer Immunotherapies Product Portfolios and Specifications
Table 127. AbbVie Cancer Immunotherapies Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2020-2025)
Table 128. AbbVie Main Business
Table 129. AbbVie Latest Developments
Table 130. Gilead Sciences Basic Information, Cancer Immunotherapies Manufacturing Base, Sales Area and Its Competitors
Table 131. Gilead Sciences Cancer Immunotherapies Product Portfolios and Specifications
Table 132. Gilead Sciences Cancer Immunotherapies Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2020-2025)
Table 133. Gilead Sciences Main Business
Table 134. Gilead Sciences Latest Developments
Table 1. Cancer Immunotherapies Annual Sales CAGR by Geographic Region (2020, 2024 & 2031) & ($ millions)
Table 2. Cancer Immunotherapies Annual Sales CAGR by Country/Region (2020, 2024 & 2031) & ($ millions)
Table 3. Major Players of Monoclonal Antibodies (MABs)
Table 4. Major Players of Cancer Vaccines
Table 5. Major Players of Immunomodulators
Table 6. Major Players of Adoptive Cell transfer
Table 7. Major Players of Checkpoint Inhibitors
Table 8. Global Cancer Immunotherapies Sales by Type (2020-2025) & (K Units)
Table 9. Global Cancer Immunotherapies Sales Market Share by Type (2020-2025)
Table 10. Global Cancer Immunotherapies Revenue by Type (2020-2025) & ($ million)
Table 11. Global Cancer Immunotherapies Revenue Market Share by Type (2020-2025)
Table 12. Global Cancer Immunotherapies Sale Price by Type (2020-2025) & (USD/Unit)
Table 13. Global Cancer Immunotherapies Sale by Application (2020-2025) & (K Units)
Table 14. Global Cancer Immunotherapies Sale Market Share by Application (2020-2025)
Table 15. Global Cancer Immunotherapies Revenue by Application (2020-2025) & ($ million)
Table 16. Global Cancer Immunotherapies Revenue Market Share by Application (2020-2025)
Table 17. Global Cancer Immunotherapies Sale Price by Application (2020-2025) & (USD/Unit)
Table 18. Global Cancer Immunotherapies Sales by Company (2020-2025) & (K Units)
Table 19. Global Cancer Immunotherapies Sales Market Share by Company (2020-2025)
Table 20. Global Cancer Immunotherapies Revenue by Company (2020-2025) & ($ millions)
Table 21. Global Cancer Immunotherapies Revenue Market Share by Company (2020-2025)
Table 22. Global Cancer Immunotherapies Sale Price by Company (2020-2025) & (USD/Unit)
Table 23. Key Manufacturers Cancer Immunotherapies Producing Area Distribution and Sales Area
Table 24. Players Cancer Immunotherapies Products Offered
Table 25. Cancer Immunotherapies Concentration Ratio (CR3, CR5 and CR10) & (2023-2025)
Table 26. New Products and Potential Entrants
Table 27. Market M&A Activity & Strategy
Table 28. Global Cancer Immunotherapies Sales by Geographic Region (2020-2025) & (K Units)
Table 29. Global Cancer Immunotherapies Sales Market Share Geographic Region (2020-2025)
Table 30. Global Cancer Immunotherapies Revenue by Geographic Region (2020-2025) & ($ millions)
Table 31. Global Cancer Immunotherapies Revenue Market Share by Geographic Region (2020-2025)
Table 32. Global Cancer Immunotherapies Sales by Country/Region (2020-2025) & (K Units)
Table 33. Global Cancer Immunotherapies Sales Market Share by Country/Region (2020-2025)
Table 34. Global Cancer Immunotherapies Revenue by Country/Region (2020-2025) & ($ millions)
Table 35. Global Cancer Immunotherapies Revenue Market Share by Country/Region (2020-2025)
Table 36. Americas Cancer Immunotherapies Sales by Country (2020-2025) & (K Units)
Table 37. Americas Cancer Immunotherapies Sales Market Share by Country (2020-2025)
Table 38. Americas Cancer Immunotherapies Revenue by Country (2020-2025) & ($ millions)
Table 39. Americas Cancer Immunotherapies Sales by Type (2020-2025) & (K Units)
Table 40. Americas Cancer Immunotherapies Sales by Application (2020-2025) & (K Units)
Table 41. APAC Cancer Immunotherapies Sales by Region (2020-2025) & (K Units)
Table 42. APAC Cancer Immunotherapies Sales Market Share by Region (2020-2025)
Table 43. APAC Cancer Immunotherapies Revenue by Region (2020-2025) & ($ millions)
Table 44. APAC Cancer Immunotherapies Sales by Type (2020-2025) & (K Units)
Table 45. APAC Cancer Immunotherapies Sales by Application (2020-2025) & (K Units)
Table 46. Europe Cancer Immunotherapies Sales by Country (2020-2025) & (K Units)
Table 47. Europe Cancer Immunotherapies Revenue by Country (2020-2025) & ($ millions)
Table 48. Europe Cancer Immunotherapies Sales by Type (2020-2025) & (K Units)
Table 49. Europe Cancer Immunotherapies Sales by Application (2020-2025) & (K Units)
Table 50. Middle East & Africa Cancer Immunotherapies Sales by Country (2020-2025) & (K Units)
Table 51. Middle East & Africa Cancer Immunotherapies Revenue Market Share by Country (2020-2025)
Table 52. Middle East & Africa Cancer Immunotherapies Sales by Type (2020-2025) & (K Units)
Table 53. Middle East & Africa Cancer Immunotherapies Sales by Application (2020-2025) & (K Units)
Table 54. Key Market Drivers & Growth Opportunities of Cancer Immunotherapies
Table 55. Key Market Challenges & Risks of Cancer Immunotherapies
Table 56. Key Industry Trends of Cancer Immunotherapies
Table 57. Cancer Immunotherapies Raw Material
Table 58. Key Suppliers of Raw Materials
Table 59. Cancer Immunotherapies Distributors List
Table 60. Cancer Immunotherapies Customer List
Table 61. Global Cancer Immunotherapies Sales Forecast by Region (2026-2031) & (K Units)
Table 62. Global Cancer Immunotherapies Revenue Forecast by Region (2026-2031) & ($ millions)
Table 63. Americas Cancer Immunotherapies Sales Forecast by Country (2026-2031) & (K Units)
Table 64. Americas Cancer Immunotherapies Annual Revenue Forecast by Country (2026-2031) & ($ millions)
Table 65. APAC Cancer Immunotherapies Sales Forecast by Region (2026-2031) & (K Units)
Table 66. APAC Cancer Immunotherapies Annual Revenue Forecast by Region (2026-2031) & ($ millions)
Table 67. Europe Cancer Immunotherapies Sales Forecast by Country (2026-2031) & (K Units)
Table 68. Europe Cancer Immunotherapies Revenue Forecast by Country (2026-2031) & ($ millions)
Table 69. Middle East & Africa Cancer Immunotherapies Sales Forecast by Country (2026-2031) & (K Units)
Table 70. Middle East & Africa Cancer Immunotherapies Revenue Forecast by Country (2026-2031) & ($ millions)
Table 71. Global Cancer Immunotherapies Sales Forecast by Type (2026-2031) & (K Units)
Table 72. Global Cancer Immunotherapies Revenue Forecast by Type (2026-2031) & ($ millions)
Table 73. Global Cancer Immunotherapies Sales Forecast by Application (2026-2031) & (K Units)
Table 74. Global Cancer Immunotherapies Revenue Forecast by Application (2026-2031) & ($ millions)
Table 75. Amgen Basic Information, Cancer Immunotherapies Manufacturing Base, Sales Area and Its Competitors
Table 76. Amgen Cancer Immunotherapies Product Portfolios and Specifications
Table 77. Amgen Cancer Immunotherapies Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2020-2025)
Table 78. Amgen Main Business
Table 79. Amgen Latest Developments
Table 80. AstraZeneca Basic Information, Cancer Immunotherapies Manufacturing Base, Sales Area and Its Competitors
Table 81. AstraZeneca Cancer Immunotherapies Product Portfolios and Specifications
Table 82. AstraZeneca Cancer Immunotherapies Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2020-2025)
Table 83. AstraZeneca Main Business
Table 84. AstraZeneca Latest Developments
Table 85. Roche Basic Information, Cancer Immunotherapies Manufacturing Base, Sales Area and Its Competitors
Table 86. Roche Cancer Immunotherapies Product Portfolios and Specifications
Table 87. Roche Cancer Immunotherapies Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2020-2025)
Table 88. Roche Main Business
Table 89. Roche Latest Developments
Table 90. Bristol-Myers Squibb Basic Information, Cancer Immunotherapies Manufacturing Base, Sales Area and Its Competitors
Table 91. Bristol-Myers Squibb Cancer Immunotherapies Product Portfolios and Specifications
Table 92. Bristol-Myers Squibb Cancer Immunotherapies Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2020-2025)
Table 93. Bristol-Myers Squibb Main Business
Table 94. Bristol-Myers Squibb Latest Developments
Table 95. Bayer Basic Information, Cancer Immunotherapies Manufacturing Base, Sales Area and Its Competitors
Table 96. Bayer Cancer Immunotherapies Product Portfolios and Specifications
Table 97. Bayer Cancer Immunotherapies Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2020-2025)
Table 98. Bayer Main Business
Table 99. Bayer Latest Developments
Table 100. Merck Basic Information, Cancer Immunotherapies Manufacturing Base, Sales Area and Its Competitors
Table 101. Merck Cancer Immunotherapies Product Portfolios and Specifications
Table 102. Merck Cancer Immunotherapies Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2020-2025)
Table 103. Merck Main Business
Table 104. Merck Latest Developments
Table 105. ARMO BioSciences (Eli Lilly) Basic Information, Cancer Immunotherapies Manufacturing Base, Sales Area and Its Competitors
Table 106. ARMO BioSciences (Eli Lilly) Cancer Immunotherapies Product Portfolios and Specifications
Table 107. ARMO BioSciences (Eli Lilly) Cancer Immunotherapies Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2020-2025)
Table 108. ARMO BioSciences (Eli Lilly) Main Business
Table 109. ARMO BioSciences (Eli Lilly) Latest Developments
Table 110. Novartis Basic Information, Cancer Immunotherapies Manufacturing Base, Sales Area and Its Competitors
Table 111. Novartis Cancer Immunotherapies Product Portfolios and Specifications
Table 112. Novartis Cancer Immunotherapies Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2020-2025)
Table 113. Novartis Main Business
Table 114. Novartis Latest Developments
Table 115. Pfizer Basic Information, Cancer Immunotherapies Manufacturing Base, Sales Area and Its Competitors
Table 116. Pfizer Cancer Immunotherapies Product Portfolios and Specifications
Table 117. Pfizer Cancer Immunotherapies Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2020-2025)
Table 118. Pfizer Main Business
Table 119. Pfizer Latest Developments
Table 120. Johnson & Johnson Basic Information, Cancer Immunotherapies Manufacturing Base, Sales Area and Its Competitors
Table 121. Johnson & Johnson Cancer Immunotherapies Product Portfolios and Specifications
Table 122. Johnson & Johnson Cancer Immunotherapies Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2020-2025)
Table 123. Johnson & Johnson Main Business
Table 124. Johnson & Johnson Latest Developments
Table 125. AbbVie Basic Information, Cancer Immunotherapies Manufacturing Base, Sales Area and Its Competitors
Table 126. AbbVie Cancer Immunotherapies Product Portfolios and Specifications
Table 127. AbbVie Cancer Immunotherapies Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2020-2025)
Table 128. AbbVie Main Business
Table 129. AbbVie Latest Developments
Table 130. Gilead Sciences Basic Information, Cancer Immunotherapies Manufacturing Base, Sales Area and Its Competitors
Table 131. Gilead Sciences Cancer Immunotherapies Product Portfolios and Specifications
Table 132. Gilead Sciences Cancer Immunotherapies Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2020-2025)
Table 133. Gilead Sciences Main Business
Table 134. Gilead Sciences Latest Developments
LIST OF FIGURES
Figure 1. Picture of Cancer Immunotherapies
Figure 2. Cancer Immunotherapies Report Years Considered
Figure 3. Research Objectives
Figure 4. Research Methodology
Figure 5. Research Process and Data Source
Figure 6. Global Cancer Immunotherapies Sales Growth Rate 2020-2031 (K Units)
Figure 7. Global Cancer Immunotherapies Revenue Growth Rate 2020-2031 ($ millions)
Figure 8. Cancer Immunotherapies Sales by Geographic Region (2020, 2024 & 2031) & ($ millions)
Figure 9. Cancer Immunotherapies Sales Market Share by Country/Region (2024)
Figure 10. Cancer Immunotherapies Sales Market Share by Country/Region (2020, 2024 & 2031)
Figure 11. Product Picture of Monoclonal Antibodies (MABs)
Figure 12. Product Picture of Cancer Vaccines
Figure 13. Product Picture of Immunomodulators
Figure 14. Product Picture of Adoptive Cell transfer
Figure 15. Product Picture of Checkpoint Inhibitors
Figure 16. Global Cancer Immunotherapies Sales Market Share by Type in 2025
Figure 17. Global Cancer Immunotherapies Revenue Market Share by Type (2020-2025)
Figure 18. Cancer Immunotherapies Consumed in Breast Cancer
Figure 19. Global Cancer Immunotherapies Market: Breast Cancer (2020-2025) & (K Units)
Figure 20. Cancer Immunotherapies Consumed in Leukemia
Figure 21. Global Cancer Immunotherapies Market: Leukemia (2020-2025) & (K Units)
Figure 22. Cancer Immunotherapies Consumed in Lymphoma
Figure 23. Global Cancer Immunotherapies Market: Lymphoma (2020-2025) & (K Units)
Figure 24. Cancer Immunotherapies Consumed in Melanoma
Figure 25. Global Cancer Immunotherapies Market: Melanoma (2020-2025) & (K Units)
Figure 26. Cancer Immunotherapies Consumed in Colorectal Cancer
Figure 27. Global Cancer Immunotherapies Market: Colorectal Cancer (2020-2025) & (K Units)
Figure 28. Cancer Immunotherapies Consumed in Non-Small Cell Lung Cancer
Figure 29. Global Cancer Immunotherapies Market: Non-Small Cell Lung Cancer (2020-2025) & (K Units)
Figure 30. Global Cancer Immunotherapies Sale Market Share by Application (2024)
Figure 31. Global Cancer Immunotherapies Revenue Market Share by Application in 2025
Figure 32. Cancer Immunotherapies Sales by Company in 2025 (K Units)
Figure 33. Global Cancer Immunotherapies Sales Market Share by Company in 2025
Figure 34. Cancer Immunotherapies Revenue by Company in 2025 ($ millions)
Figure 35. Global Cancer Immunotherapies Revenue Market Share by Company in 2025
Figure 36. Global Cancer Immunotherapies Sales Market Share by Geographic Region (2020-2025)
Figure 37. Global Cancer Immunotherapies Revenue Market Share by Geographic Region in 2025
Figure 38. Americas Cancer Immunotherapies Sales 2020-2025 (K Units)
Figure 39. Americas Cancer Immunotherapies Revenue 2020-2025 ($ millions)
Figure 40. APAC Cancer Immunotherapies Sales 2020-2025 (K Units)
Figure 41. APAC Cancer Immunotherapies Revenue 2020-2025 ($ millions)
Figure 42. Europe Cancer Immunotherapies Sales 2020-2025 (K Units)
Figure 43. Europe Cancer Immunotherapies Revenue 2020-2025 ($ millions)
Figure 44. Middle East & Africa Cancer Immunotherapies Sales 2020-2025 (K Units)
Figure 45. Middle East & Africa Cancer Immunotherapies Revenue 2020-2025 ($ millions)
Figure 46. Americas Cancer Immunotherapies Sales Market Share by Country in 2025
Figure 47. Americas Cancer Immunotherapies Revenue Market Share by Country (2020-2025)
Figure 48. Americas Cancer Immunotherapies Sales Market Share by Type (2020-2025)
Figure 49. Americas Cancer Immunotherapies Sales Market Share by Application (2020-2025)
Figure 50. United States Cancer Immunotherapies Revenue Growth 2020-2025 ($ millions)
Figure 51. Canada Cancer Immunotherapies Revenue Growth 2020-2025 ($ millions)
Figure 52. Mexico Cancer Immunotherapies Revenue Growth 2020-2025 ($ millions)
Figure 53. Brazil Cancer Immunotherapies Revenue Growth 2020-2025 ($ millions)
Figure 54. APAC Cancer Immunotherapies Sales Market Share by Region in 2025
Figure 55. APAC Cancer Immunotherapies Revenue Market Share by Region (2020-2025)
Figure 56. APAC Cancer Immunotherapies Sales Market Share by Type (2020-2025)
Figure 57. APAC Cancer Immunotherapies Sales Market Share by Application (2020-2025)
Figure 58. China Cancer Immunotherapies Revenue Growth 2020-2025 ($ millions)
Figure 59. Japan Cancer Immunotherapies Revenue Growth 2020-2025 ($ millions)
Figure 60. South Korea Cancer Immunotherapies Revenue Growth 2020-2025 ($ millions)
Figure 61. Southeast Asia Cancer Immunotherapies Revenue Growth 2020-2025 ($ millions)
Figure 62. India Cancer Immunotherapies Revenue Growth 2020-2025 ($ millions)
Figure 63. Australia Cancer Immunotherapies Revenue Growth 2020-2025 ($ millions)
Figure 64. China Taiwan Cancer Immunotherapies Revenue Growth 2020-2025 ($ millions)
Figure 65. Europe Cancer Immunotherapies Sales Market Share by Country in 2025
Figure 66. Europe Cancer Immunotherapies Revenue Market Share by Country (2020-2025)
Figure 67. Europe Cancer Immunotherapies Sales Market Share by Type (2020-2025)
Figure 68. Europe Cancer Immunotherapies Sales Market Share by Application (2020-2025)
Figure 69. Germany Cancer Immunotherapies Revenue Growth 2020-2025 ($ millions)
Figure 70. France Cancer Immunotherapies Revenue Growth 2020-2025 ($ millions)
Figure 71. UK Cancer Immunotherapies Revenue Growth 2020-2025 ($ millions)
Figure 72. Italy Cancer Immunotherapies Revenue Growth 2020-2025 ($ millions)
Figure 73. Russia Cancer Immunotherapies Revenue Growth 2020-2025 ($ millions)
Figure 74. Middle East & Africa Cancer Immunotherapies Sales Market Share by Country (2020-2025)
Figure 75. Middle East & Africa Cancer Immunotherapies Sales Market Share by Type (2020-2025)
Figure 76. Middle East & Africa Cancer Immunotherapies Sales Market Share by Application (2020-2025)
Figure 77. Egypt Cancer Immunotherapies Revenue Growth 2020-2025 ($ millions)
Figure 78. South Africa Cancer Immunotherapies Revenue Growth 2020-2025 ($ millions)
Figure 79. Israel Cancer Immunotherapies Revenue Growth 2020-2025 ($ millions)
Figure 80. Turkey Cancer Immunotherapies Revenue Growth 2020-2025 ($ millions)
Figure 81. GCC Countries Cancer Immunotherapies Revenue Growth 2020-2025 ($ millions)
Figure 82. Manufacturing Cost Structure Analysis of Cancer Immunotherapies in 2025
Figure 83. Manufacturing Process Analysis of Cancer Immunotherapies
Figure 84. Industry Chain Structure of Cancer Immunotherapies
Figure 85. Channels of Distribution
Figure 86. Global Cancer Immunotherapies Sales Market Forecast by Region (2026-2031)
Figure 87. Global Cancer Immunotherapies Revenue Market Share Forecast by Region (2026-2031)
Figure 88. Global Cancer Immunotherapies Sales Market Share Forecast by Type (2026-2031)
Figure 89. Global Cancer Immunotherapies Revenue Market Share Forecast by Type (2026-2031)
Figure 90. Global Cancer Immunotherapies Sales Market Share Forecast by Application (2026-2031)
Figure 91. Global Cancer Immunotherapies Revenue Market Share Forecast by Application (2026-2031)
Figure 1. Picture of Cancer Immunotherapies
Figure 2. Cancer Immunotherapies Report Years Considered
Figure 3. Research Objectives
Figure 4. Research Methodology
Figure 5. Research Process and Data Source
Figure 6. Global Cancer Immunotherapies Sales Growth Rate 2020-2031 (K Units)
Figure 7. Global Cancer Immunotherapies Revenue Growth Rate 2020-2031 ($ millions)
Figure 8. Cancer Immunotherapies Sales by Geographic Region (2020, 2024 & 2031) & ($ millions)
Figure 9. Cancer Immunotherapies Sales Market Share by Country/Region (2024)
Figure 10. Cancer Immunotherapies Sales Market Share by Country/Region (2020, 2024 & 2031)
Figure 11. Product Picture of Monoclonal Antibodies (MABs)
Figure 12. Product Picture of Cancer Vaccines
Figure 13. Product Picture of Immunomodulators
Figure 14. Product Picture of Adoptive Cell transfer
Figure 15. Product Picture of Checkpoint Inhibitors
Figure 16. Global Cancer Immunotherapies Sales Market Share by Type in 2025
Figure 17. Global Cancer Immunotherapies Revenue Market Share by Type (2020-2025)
Figure 18. Cancer Immunotherapies Consumed in Breast Cancer
Figure 19. Global Cancer Immunotherapies Market: Breast Cancer (2020-2025) & (K Units)
Figure 20. Cancer Immunotherapies Consumed in Leukemia
Figure 21. Global Cancer Immunotherapies Market: Leukemia (2020-2025) & (K Units)
Figure 22. Cancer Immunotherapies Consumed in Lymphoma
Figure 23. Global Cancer Immunotherapies Market: Lymphoma (2020-2025) & (K Units)
Figure 24. Cancer Immunotherapies Consumed in Melanoma
Figure 25. Global Cancer Immunotherapies Market: Melanoma (2020-2025) & (K Units)
Figure 26. Cancer Immunotherapies Consumed in Colorectal Cancer
Figure 27. Global Cancer Immunotherapies Market: Colorectal Cancer (2020-2025) & (K Units)
Figure 28. Cancer Immunotherapies Consumed in Non-Small Cell Lung Cancer
Figure 29. Global Cancer Immunotherapies Market: Non-Small Cell Lung Cancer (2020-2025) & (K Units)
Figure 30. Global Cancer Immunotherapies Sale Market Share by Application (2024)
Figure 31. Global Cancer Immunotherapies Revenue Market Share by Application in 2025
Figure 32. Cancer Immunotherapies Sales by Company in 2025 (K Units)
Figure 33. Global Cancer Immunotherapies Sales Market Share by Company in 2025
Figure 34. Cancer Immunotherapies Revenue by Company in 2025 ($ millions)
Figure 35. Global Cancer Immunotherapies Revenue Market Share by Company in 2025
Figure 36. Global Cancer Immunotherapies Sales Market Share by Geographic Region (2020-2025)
Figure 37. Global Cancer Immunotherapies Revenue Market Share by Geographic Region in 2025
Figure 38. Americas Cancer Immunotherapies Sales 2020-2025 (K Units)
Figure 39. Americas Cancer Immunotherapies Revenue 2020-2025 ($ millions)
Figure 40. APAC Cancer Immunotherapies Sales 2020-2025 (K Units)
Figure 41. APAC Cancer Immunotherapies Revenue 2020-2025 ($ millions)
Figure 42. Europe Cancer Immunotherapies Sales 2020-2025 (K Units)
Figure 43. Europe Cancer Immunotherapies Revenue 2020-2025 ($ millions)
Figure 44. Middle East & Africa Cancer Immunotherapies Sales 2020-2025 (K Units)
Figure 45. Middle East & Africa Cancer Immunotherapies Revenue 2020-2025 ($ millions)
Figure 46. Americas Cancer Immunotherapies Sales Market Share by Country in 2025
Figure 47. Americas Cancer Immunotherapies Revenue Market Share by Country (2020-2025)
Figure 48. Americas Cancer Immunotherapies Sales Market Share by Type (2020-2025)
Figure 49. Americas Cancer Immunotherapies Sales Market Share by Application (2020-2025)
Figure 50. United States Cancer Immunotherapies Revenue Growth 2020-2025 ($ millions)
Figure 51. Canada Cancer Immunotherapies Revenue Growth 2020-2025 ($ millions)
Figure 52. Mexico Cancer Immunotherapies Revenue Growth 2020-2025 ($ millions)
Figure 53. Brazil Cancer Immunotherapies Revenue Growth 2020-2025 ($ millions)
Figure 54. APAC Cancer Immunotherapies Sales Market Share by Region in 2025
Figure 55. APAC Cancer Immunotherapies Revenue Market Share by Region (2020-2025)
Figure 56. APAC Cancer Immunotherapies Sales Market Share by Type (2020-2025)
Figure 57. APAC Cancer Immunotherapies Sales Market Share by Application (2020-2025)
Figure 58. China Cancer Immunotherapies Revenue Growth 2020-2025 ($ millions)
Figure 59. Japan Cancer Immunotherapies Revenue Growth 2020-2025 ($ millions)
Figure 60. South Korea Cancer Immunotherapies Revenue Growth 2020-2025 ($ millions)
Figure 61. Southeast Asia Cancer Immunotherapies Revenue Growth 2020-2025 ($ millions)
Figure 62. India Cancer Immunotherapies Revenue Growth 2020-2025 ($ millions)
Figure 63. Australia Cancer Immunotherapies Revenue Growth 2020-2025 ($ millions)
Figure 64. China Taiwan Cancer Immunotherapies Revenue Growth 2020-2025 ($ millions)
Figure 65. Europe Cancer Immunotherapies Sales Market Share by Country in 2025
Figure 66. Europe Cancer Immunotherapies Revenue Market Share by Country (2020-2025)
Figure 67. Europe Cancer Immunotherapies Sales Market Share by Type (2020-2025)
Figure 68. Europe Cancer Immunotherapies Sales Market Share by Application (2020-2025)
Figure 69. Germany Cancer Immunotherapies Revenue Growth 2020-2025 ($ millions)
Figure 70. France Cancer Immunotherapies Revenue Growth 2020-2025 ($ millions)
Figure 71. UK Cancer Immunotherapies Revenue Growth 2020-2025 ($ millions)
Figure 72. Italy Cancer Immunotherapies Revenue Growth 2020-2025 ($ millions)
Figure 73. Russia Cancer Immunotherapies Revenue Growth 2020-2025 ($ millions)
Figure 74. Middle East & Africa Cancer Immunotherapies Sales Market Share by Country (2020-2025)
Figure 75. Middle East & Africa Cancer Immunotherapies Sales Market Share by Type (2020-2025)
Figure 76. Middle East & Africa Cancer Immunotherapies Sales Market Share by Application (2020-2025)
Figure 77. Egypt Cancer Immunotherapies Revenue Growth 2020-2025 ($ millions)
Figure 78. South Africa Cancer Immunotherapies Revenue Growth 2020-2025 ($ millions)
Figure 79. Israel Cancer Immunotherapies Revenue Growth 2020-2025 ($ millions)
Figure 80. Turkey Cancer Immunotherapies Revenue Growth 2020-2025 ($ millions)
Figure 81. GCC Countries Cancer Immunotherapies Revenue Growth 2020-2025 ($ millions)
Figure 82. Manufacturing Cost Structure Analysis of Cancer Immunotherapies in 2025
Figure 83. Manufacturing Process Analysis of Cancer Immunotherapies
Figure 84. Industry Chain Structure of Cancer Immunotherapies
Figure 85. Channels of Distribution
Figure 86. Global Cancer Immunotherapies Sales Market Forecast by Region (2026-2031)
Figure 87. Global Cancer Immunotherapies Revenue Market Share Forecast by Region (2026-2031)
Figure 88. Global Cancer Immunotherapies Sales Market Share Forecast by Type (2026-2031)
Figure 89. Global Cancer Immunotherapies Revenue Market Share Forecast by Type (2026-2031)
Figure 90. Global Cancer Immunotherapies Sales Market Share Forecast by Application (2026-2031)
Figure 91. Global Cancer Immunotherapies Revenue Market Share Forecast by Application (2026-2031)
